Avalon GloboCare (ALBT) Competitors $2.80 +0.08 (+2.94%) Closing price 03:59 PM EasternExtended Trading$2.82 +0.02 (+0.71%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. RVPH, THAR, ITRM, RNTX, KZR, CASI, PMN, ASBP, DARE, and CLSDShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Reviva Pharmaceuticals (RVPH), Tharimmune (THAR), Iterum Therapeutics (ITRM), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Promis Neurosciences (PMN), Aspire Biopharma (ASBP), Dare Bioscience (DARE), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Its Competitors Reviva Pharmaceuticals Tharimmune Iterum Therapeutics Rein Therapeutics Kezar Life Sciences CASI Pharmaceuticals Promis Neurosciences Aspire Biopharma Dare Bioscience Clearside Biomedical Reviva Pharmaceuticals (NASDAQ:RVPH) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Is RVPH or ALBT more profitable? Reviva Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -259.17% Avalon GloboCare -1,451.94%N/A -75.12% Which has more volatility and risk, RVPH or ALBT? Reviva Pharmaceuticals has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Do insiders & institutionals have more ownership in RVPH or ALBT? 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 27.2% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to RVPH or ALBT? In the previous week, Reviva Pharmaceuticals and Reviva Pharmaceuticals both had 2 articles in the media. Reviva Pharmaceuticals' average media sentiment score of 0.59 beat Avalon GloboCare's score of 0.45 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Reviva Pharmaceuticals Positive Avalon GloboCare Neutral Do analysts recommend RVPH or ALBT? Reviva Pharmaceuticals currently has a consensus target price of $5.20, suggesting a potential upside of 1,075.67%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings and valuation, RVPH or ALBT? Avalon GloboCare has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.68Avalon GloboCare$1.33M8.08-$7.90M-$19.96-0.14 SummaryReviva Pharmaceuticals beats Avalon GloboCare on 8 of the 14 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.75M$3.13B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.60%P/E Ratio-0.1421.3074.5925.92Price / Sales8.08257.21453.5485.33Price / CashN/A45.3337.0859.91Price / Book-0.259.6112.156.29Net Income-$7.90M-$53.29M$3.28B$270.77M7 Day Performance20.69%0.28%0.99%3.36%1 Month Performance30.23%8.91%7.21%6.41%1 Year Performance-24.58%13.14%63.07%28.24% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare0.942 of 5 stars$2.80+2.9%N/A-39.6%$10.75M$1.33M-0.145Short Interest ↑Gap UpRVPHReviva Pharmaceuticals2.9989 of 5 stars$0.45+0.7%$5.20+1,047.9%-65.9%$30.80MN/A-0.705THARTharimmune2.4631 of 5 stars$5.26-11.6%$17.00+223.2%+6.1%$29.93MN/A-0.862Short Interest ↑Gap UpITRMIterum Therapeutics2.8487 of 5 stars$0.66-2.2%$9.00+1,259.5%-32.8%$29.57MN/A-0.7810Positive NewsShort Interest ↓RNTXRein Therapeutics1.019 of 5 stars$1.26-9.4%N/AN/A$29.37MN/A-0.479News CoveragePositive NewsGap DownKZRKezar Life Sciences3.864 of 5 stars$3.93-0.5%$9.00+129.0%-31.1%$28.77M$7M-0.4160CASICASI Pharmaceuticals3.7727 of 5 stars$2.27-1.9%$4.00+76.6%-69.1%$28.03M$28.54M-0.79180PMNPromis Neurosciences3.6842 of 5 stars$0.54+0.2%$4.33+701.0%-66.0%$28.03MN/A-2.585Positive NewsShort Interest ↓ASBPAspire BiopharmaN/A$0.56-3.0%N/AN/A$27.64MN/A0.00N/APositive NewsDAREDare Bioscience2.3002 of 5 stars$2.04+1.0%$12.00+488.2%-35.3%$27.50M$10K-0.9530Positive NewsShort Interest ↓CLSDClearside Biomedical2.2122 of 5 stars$0.35-4.8%$4.20+1,100.0%-73.3%$27.48M$1.66M-0.9530Stock SplitGap Down Related Companies and Tools Related Companies Reviva Pharmaceuticals Competitors Tharimmune Competitors Iterum Therapeutics Competitors Rein Therapeutics Competitors Kezar Life Sciences Competitors CASI Pharmaceuticals Competitors Promis Neurosciences Competitors Aspire Biopharma Competitors Dare Bioscience Competitors Clearside Biomedical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBT Stock Alerts